Tesselaar M E, Wijermans P W, Metsaars J A, Gerrits W B, Haak H L
Afd. Hematologie, Ziekenhuis Leyenburg, Den Haag.
Ned Tijdschr Geneeskd. 1996 Sep 21;140(38):1900-2.
To determine if there is a place for radiophosphorus (32P) in the treatment of polycythaemia vera (PV) and essential thrombocytosis (ET).
Retrospective.
Leyenburg Hospital, The Hague, the Netherlands.
Data on 144 patients with the diagnoses 'PV' or 'ET' from 1965 to 1994 were collected. Available data were insufficient in 19 of these. Regarding 125 patients, 80 with PV and 45 with ET, the survival and the frequency of acute leukaemia with various forms of treatment (32P, busulfan or combination of several treatment modalities) were studied. Moreover, in the PV group the duration of survival was compared with the expected duration of survival in a comparable group of the population.
Of the 80 PV patients, five developed acute leukaemia: two in the 32P group (5%), two in the busulfan group (12%) and one in the group given combination therapy (4%). Of the 26 patients of the ET group treated with busulfan, one developed acute leukaemia (4%). The survival in the PV group was 4 years shorter than the expected duration of survival in a comparable group of the population.
Since 32P is efficacious and causes little inconvenience, it should be the drug of first choice in the treatment of PV in the elderly.
确定放射性磷（32P）在真性红细胞增多症（PV）和原发性血小板增多症（ET）治疗中是否有一席之地。
回顾性研究。
荷兰海牙莱嫩堡医院。
收集了1965年至1994年期间144例诊断为“PV”或“ET”患者的数据。其中19例患者的可用数据不足。对125例患者（80例PV患者和45例ET患者），研究了采用不同治疗方式（32P、白消安或多种治疗方式联合）时的生存率和急性白血病发生率。此外，在PV组中，将生存时间与可比人群组的预期生存时间进行了比较。
80例PV患者中，5例发生急性白血病：32P组2例（5%），白消安组2例（12%），联合治疗组1例（4%）。ET组26例接受白消安治疗的患者中，1例发生急性白血病（4%）。PV组的生存时间比可比人群组的预期生存时间短4年。
由于32P疗效显著且不便之处少，它应成为老年PV患者治疗的首选药物。
